CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and Medison Pharma Ltd., a leading global commercial partner for biotech and pharma companies that operates in Israel, Canada, and Central and Eastern Europe, today announced an exclusive distribution agreement for Medison to commercialize BeiGene’s BTK inhibitor BRUKINSA™ (zanubrutinib) in Israel and the acceptance of a new drug application (NDA) in Israel for BRUKINSA for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
“Our first distribution agreement for BRUKINSA and the acceptance of our first NDA outside of the United States and China marks a significant step in realizing our global commercialization plans. We are excited to work with Medison, a leader in drug commercialization with extensive experience, to bring our potentially best-in-class BTK inhibitor to patients in Israel,” commented Howard Liang, Ph.D., CFO and Chief Strategy Officer of BeiGene. “In addition, our planned expansion into new markets illustrates BeiGene’s patient-first principle and commitment to bringing meaningful treatments to patients worldwide.”
"We are thrilled and inspired by the opportunity to help patients by enabling access to BRUKINSA, and we plan to work closely with regulators to bring this innovative product to the market here as quickly as possible,” said Meir Jakobsohn, Founder and CEO, Medison Pharma. "We are happy to find in BeiGene a partner that understands the mutual value our companies can unlock together and are honored to be the first company in the world to sign a distribution agreement with BeiGene for BRUKINSA."
For the complete Press Release: https://www.globenewswire.com